Gutiérrez ZA

Language: Spanish
References: 16
Page: 90-95
PDF size: 84.95 Kb.

ABSTRACT

Cardiomyopathies encompass a broad spectrum of heart pathologies having a basic principle, the intrinsic injury of the myocardial fiber. By definition, cardiomyopathies could be primary (dilated cardiomyopathy), or can be a consequence of another cardiovascular illness (high blood pressure), or of genetic anomalies, such as hypertrophic cardiomyopathy, or due to alterations in myocytes due to fibrolipidic material as occurs in right ventricle arrhythmogenic dysplasia. Currently, magnetic resonance imaging is the best method to approach the diagnosis of these pathologies. Magnetic resonance imaging has allowed us to study histological sections through adequate sequences and using gadolinium as contrast agent. We present herein a simple way to approach the diagnosis of cardiomyopathies by means of magnetic resonance imaging methods.

REFERENCES

1. MacKenna RP: Report of the 1995 Worl Health Organization/International Society and Federation of Cardiology Task Forceon the Definition and the Classification of Cardiomyopathies. Circulation 1996 ; 93: 841-842.

2. Sodikson DK: Clinical Cardiovascular Magnetic resonance Imaging Techniques. Manning, WJ. Pennel, DJ. Cardiovascular Magnetic Resonance. Philadelphia, Penn. Churchill, Livingstone. 2002: 18-30.

3. McKrohon JA, Moon JCC, Prasad SK, McKenna DJ, Lorenz CH, Coats AJ, Pennell D: Differentiation of Heart Failure to Dilated Cardiomyopathy and Coronary Artery Disease using Gadolinium-Enhanced Cardiovascular Magnetic Resonance. Circulation 2003; 108: 54-9.

4. Di Cesare E: MRI of the Cardiomyopathies. European Journal of Radiology 2001; 38: 179-84.

5. Mahrholrdt H, Goedecke C, Wagner A, Meinhardt G, Athanasiadis A, Volgelsberg H, et al: Cardiovascular Magnetic Resonance Assessment of Human Myocarditis. A comparison of histology and molecular pathology. Circulation 2004; 109: 1250-1258.

6. Nishimura RA, Ommen SR, Tajik AJ: Hypertrophic Cardiomyopathy. A patient perspective. Circulation 2003; 108: e133-e135.

7. Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, et al: Efficacy of implantable cardioverter-desfibrillators for the prevention of sudden death in patients with Hypertrophic cardiomyopathy. NEJM 2000; 342(6): 365-73.

8. Maron BJ, Moller JH, Seidman CE, Vincent GM, Dietz HC, Moss AJ, et al: Impact of Laboratory Molecular Diagnosis on Contemporary Diagnosis Criteria For Genetically Transmitted Cardiovascular Disease: Hypetrophic Cardiomyopathy, Long Q-T syndrome and Marfan syndrome. Circulation 1998: 1460-71.

9. Cannon RO: Assessing Risk in Hypertrophic Cardiomyopathy. NEJM 2003; 349: 16-18.

10. Cecci F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Carnici PG: Coronary Microvascular Dysfunction and prognosis in Hypertrophic Cardiomyopathy. NEJM 2003; 349: 27-35.

11. Corrado D, Basso C, Schiavon M, Thiene G: Screening for Hypertrophic Cardiomyopathy in Young Athletes. NEJM 1998; 339: 364-9.

12. Midiri M, Finazzo M, Brancarte M: Arrhythmogenic rigth ventricular dysplasia: MR features. Eur Radiol 1997; 7: 307-12.

13. Moon JC, Mundy HR, Lee PJ, Mohiaddin RH, Pennell DJ: Myocardial Fibrosis in Glycogen Storage Disease Type III. Circulation 2003; 107: e47.

14. Serra JJ, Monte GU, Mello ES, Coral GP, Ávila LF, Parga JR, et al: Cardiac Sarcoidosis Evaluated by Delayed-Enhanced Magnetic Resonance Image. Circulation 2003; 107: e188-e189.

15. Petersen SE, Mohrs OK, Horstick G, Oberholzer K, Abegunewardene N, Ruetzel K, et al. Influence of Agent Dose Contrast and Image Acquisition Time on the Quantitative Determination of Nonviable Myocardium Tissue Using Delayed Contrast-Enhanced Magnetic Resonance Image. J Cardiovasc Magnetic Resonance 2004; 6(2): 541-8.

16. Pennell DJ, Sechtmen UD, Higgins CB, Manning WJ, Pohost GM, Rademakers FE, et al: Clinical Indications for Cardiovascular Magnetic Resonance (CMR): Consensus Panel Report. J Cardiovasc Magnetic Resonance 2004; 6(4): 727-65.